CGTX News and Press, Cognition Therapeutics Inc. From 03/24/23

2023-03-24 15:00:32 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...

2023-03-23 09:26:10 ET Cognition Therapeutics, Inc. (CGTX) Q4 2022 Earnings Conference Call March 23, 2023 08:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer Andrew Einhorn - Interim ...

2023-03-23 07:48:42 ET Cognition Therapeutics press release ( NASDAQ: CGTX ): Q4 GAAP EPS of -$0.91 misses by $0.68 . On December 31, 2022, the company’s cash balance was $41.6 million. The company estimates that it has sufficient cash to fund operations and...

- Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease - Received FDA clearance for Phase 2 START Study of CT1812 in early Alzheimer’s disease - Received FDA clearance for IND for Phase 2 study of CT1812 in 240 patients with geo...

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of participants in the Phase 2 SHINE (COG0201; NCT0...

PURCHASE, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financia...

PURCHASE, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financia...

2023-03-15 10:42:34 ET Clinical-stage pharma Cognition Therapeutics ( NASDAQ: CGTX ) announced Wednesday that the FDA cleared its Investigational New Drug (IND) application for the oral eye disease candidate CT1812. The IND was aimed at studying CT1812 for geographic atrop...

PURCHASE, N.Y., March 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s president and CEO, Lisa Ricciardi will present at the annual Oppenheimer & Co Healthcare Con...

Nano-cap biotech Cognition Therapeutics ( NASDAQ: CGTX ) added ~13% pre-market Wednesday after announcing that the company is set to start its Phase 2 study for lead candidate CT1812 in adults with mild cognitive impairment or early Alzheimer's disease. The 540-patient trial named...